Immune Checkpoint Inhibitors Versus CAR T-Cell Therapy

Blog
Article

The term “immunotherapy” has quite a wide scope in cancer treatment. A lot of different therapies fall within the umbrella of immunotherapy, and two of the most successful are CAR T-cell therapies and immune checkpoint inhibitors.

The term “immunotherapy” has a wide scope in cancer treatment. A lot of different therapies fall within the umbrella of immunotherapy, and two of the most popular are CAR T-cell therapies and immune checkpoint inhibitors.

What differentiates these two types of immunotherapy? Are they similar in how they help the immune system? Where do these two therapies stand in terms of effectiveness and approval for solid tumors?

What is CAR T-cell therapy?

CAR T-cell therapy is a type of cell and gene therapy that elevates the immune system cells against cancer. T cells are the body’s primary defenders against viruses, infections and other harmful elements. However, they often stumble in locating and killing cancer cells.

CAR stands for chimeric antigen receptor, which is a special laboratory-created receptor designed to bind to target proteins on cancer cells. Doctors can remove patients’ T cells to have a receptor added. Scientists develop the receptors to link with proteins highly expressed on cells of a specific cancer.

There are currently six FDA-approved CAR T-cell therapies for cancer. They are all designed for blood cancers.

What is an immune checkpoint inhibitor?

Immune checkpoint inhibitors are immunotherapy drugs that block cancerous protein actions on either cancer cells or fighter T cells. Cancer cells have masking protein receptors that can trick T cells into leaving them alone. Immune checkpoint inhibitors neutralize these protein receptors.

An example of the target protein receptor is programmed death-ligand 1 (PD-L1). This receptor links with the T cells’ programmed cell death protein 1 (PD-1). The role of PD-1 is to look for infections, viruses or cells harming the body, such as cancer. The issue is PD-L1 subdues PD-1 when T cells interact with some cancer cells. Immune checkpoint inhibitors serve as a wall between the protein receptors.

The FDA has approved several immune checkpoint inhibitors for various cancers, such as lung cancer.

Read the full blog on the Alliance for Cancer Gene Therapy website.

Related Videos
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omid Hamid, MD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
© 2024 MJH Life Sciences

All rights reserved.